Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ozempic (semaglutide) for the Treatment of Type 2 Diabetes

Drug (Brand / Generic)

Ozempic®/semaglutide

Developed by

Novo Nordisk

Therapy Class

Glucagon-like peptide (GLP-1) receptor agonist

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved in the US, Canada and Europe
Expand

Go Top